BCIQ Profiles

Company Profile ReportTarget Profile Report
0831 Versanis
BioCentury & Getty Images

Emerging Company Profile

Through Versanis, Novartis vets raise $70M to pivot pharma’s muscle therapy to fat loss

Emerging Company Profile: Versanis to remanufacture bimagrumab, run a Phase II study and develop a device combo for home use

Sep 1, 2021 | 1:59 AM GMT

With an eye toward endpoints that distinguish fat and muscle loss, Versanis aims to turn a Novartis mAb with underwhelming

Read the full 677 word article

How to gain access

Continue reading with a
two-week free trial.